Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
Saba Shafi(Ministry of Education of the People's Republic of China), David L. Rimm(Yale University), Niki Gavrielatou(National and Kapodistrian University of Athens), Thazin Nwe Aung(Yale University), Sol Langermann, Linda N. Liu(Amplimmune (United States)), Aileen I. Fernandez(Yale University), Vesal Yaghoobi(Yale University), Myrto Moutafi(University General Hospital Attikon), Ioannis Vathiotis(Yale University), Vasiliki Xirou(Yale University), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 17
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k